Celgene-CELG Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG

CELG 108.24

0.0%

Nov 22 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (479)	12/27/2000 5:44:40 AM
From: Vector1	Read Replies (3) of 804

Thanks Miljenko, a few questions: <I think that this candidate is dead.> the stock would get hit on this news. Why do you think it is dead. Competative advancements or do you believe the data will disappoint. <What combination? They still do not have clear picture about what may work well. Standard and new therapies for CC are rapidly evolving.> T's progress in CC is dependant on Irinotecan. T in combination reduces side effects and allows greater and more sustained dosage. expect it will be used in combo with T there as well. I expect some type of deal with Pharmacia on the combination. <I am not convinced yet that IMiDs will be as effective as T?> The preclinical data presented at ASH was impressive. Also one of the investigators at ASH Ken Anderson from Dan Farber apparently described what he has seen as very promising with rapid responses in all three patients he is seeing without T's side effects. The data is not out yet. What concerns you about what you have seen. <Did Novartis submitted NDA? I do not expect quick FDA review, 9 months min.> Novartis submitted in October. I agree that a 9 month review at a minimum is likely. I expect a launch in early Q3 01. The CELG/Novartis deal on ADD is one of the best I have ever seen for a biotech. CELG royalty is for all Novartis products in this area. Novartis still has significant marketing power and will in this area. By the way I agree with your comments about managements "impotence" regarding off label use of T for other cancer indications. I think management is concerned about crossing the FDA which has a sharp eye on T marketing. In managements defence they did receive a warning letter from the FDA last year. I hope you are having a great holiday season. Time will tell on this one but I must say your comments have made me go back and and re-evaluate a stock I was very comfortable. I am no longer as comfortatble but I still a buyer in the low 30s. I still think T will be the standard of care in MM and at current they have less than 10% of that market. Can't seem to get to sleep tonight V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next